Tang Shenghui - Center for Drug Evaluation and Research (CDER), US Food and Drug Administration

基本信息

浏览量：16

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 148 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Supplementary Table S4 from FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

William F. Maguire,Daniel Lee,Chana Weinstock,Xin Gao,Catharine C. Bulik,Sundeep Agrawal,Elaine Chang,Salaheldin S. Hamed,Erik W. Bloomquist,Shenghui Tang,Richard Pazdur,Paul G. Kluetz,Laleh Amiri-Kordestani,Daniel L. Suzman

crossref（2024）

引用0浏览0引用

FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

Michael J Fusco,Sandra J Casak,Sirisha L Mushti,Joyce Cheng, Brian J Christmas,Matthew D Thompson,Wentao Fu,Hezhen Wang,Miyoung Yoon,Yuching Yang, Jason N Moore,Youwei Bi, Yang Nan, Craig E Long,Doris Auth,Nam A Rahman,Shenghui Tang,Richard Pazdur,Lola A Fashoyin-Aje,Paul G Kluetz,Steven J Lemery

Clinical cancer research an official journal of the American Association for Cancer Researchno. 15 (2024): 3100-3104

引用0浏览0WOS引用

RE: is It Time to Reconsider the Role of Upfront Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma

Jaleh Fallah,Haley Gittleman,Chana Weinstock,Elaine Chang,Sundeep Agrawal,Shenghui Tang,Richard Pazdur,Paul G Kluetz,Daniel L Suzman,Laleh Amiri-Kordestani

Journal of the National Cancer Institute（2024）

引用0浏览0WOS引用

A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma

Elaine Chang,Jiaxi Zhou, Chi Song,Haley Gittleman,Laura Fernandes,Chana Weinstock,Michael B. Atkins,Sundeep Agrawal,Rajeshwari Sridhara,Nicole Gormley,Shenghui Tang,Daniel L. Suzman,Laleh Amiri-Kordestani,Paul G. Kluetz,Richard Pazdur,Brian I. Rini,David F. McDermott,Meredith M. Regan

CLINICAL CANCER RESEARCHno. 15 (2024): 3282-3286

引用0浏览0WOS引用

US Food and Drug Administration Approval Summary: Capivasertib with Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer with PIK3CA/AKT1/PTEN Alterations

Asma Dilawari, James Buturla,Christy Osgood, Xin Gao, Wei Chen,Tiffany K. Ricks, Timothy Schaefer, Sreedevi Avasarala,Francisca Reyes Turcu,Anand Pathak,Shyam Kalavar,Vishal Bhatnagar, Justin Collazo,Nam Atiqur Rahman,Bronwyn Mixter,Shenghui Tang,Richard Pazdur,Paul Kluetz,Laleh Amiri-Kordestani

JOURNAL OF CLINICAL ONCOLOGYno. 34 (2024)

引用0浏览0WOS引用

Supplementary Figure S1 from FDA Approval Summary: Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

crossref（2024）

引用0浏览0引用

Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients with NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials

Jonathon Vallejo,Harpreet Singh,Erin Larkins,Nicole Drezner,Biagio Ricciuti,Pallavi Mishra-Kalyani,Shenghui Tang,Julia A. Beaver,Mark M. Awad

ONCOLOGIST (2024)

引用0浏览0WOS引用

Supplementary Figure S2 from FDA Approval Summary: Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

crossref（2024）

引用0浏览0引用

FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer

Sandra J Casak,Vaibhav Kumar, Chi Song,Mengdie Yuan,Anup K Amatya,Joyce Cheng,Pallavi S Mishra-Kalyani,Shenghui Tang,Steven J Lemery,Doris Auth,Gina Davis,Paul G Kluetz,Richard Pazdur,Lola A Fashoyin-Aje

Clinical cancer research : an official journal of the American Association for Cancer Researchno. 16 (2024): 3371-3377

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn